首页> 外文期刊>Perfusion >Long term veno-venous extracorporeal life support without intravenous anticoagulation for diffuse alveolar hemorrhage
【24h】

Long term veno-venous extracorporeal life support without intravenous anticoagulation for diffuse alveolar hemorrhage

机译:长期静脉静脉体外寿命支持,无需静脉抗凝血,用于弥漫性肺泡出血

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Diffuse alveolar damage is the histologic hallmark for the acute phase of acute respiratory distress syndrome and can occasionally present as diffuse alveolar hemorrhage. Case report: We report a patient with diffuse alveolar hemorrhage and acute respiratory distress syndrome requiring veno-venous extracorporeal life support for 210 days, who was successfully treated for a period of 130 consecutive days without intravenous anticoagulation. Discussion: Although there are a few brief reports detailing long extracorporeal life support runs, the literature is largely devoid of data regarding long-term extracorporeal life support without full systemic anticoagulation. Regular inspection of the extracorporeal membrane oxygenation circuit is critical because externally visible thrombi may predict internal thrombus generation with the potential for systemic embolization or abrupt oxygenator failure. In our case, multiple circuit and oxygenators changes were required. Conclusion: We have demonstrated that a patient with a contraindication for systemic anticoagulation can safely have veno-venous extracorporeal life support for prolonged periods without catastrophic thrombotic complications.
机译:介绍:弥漫性肺泡损伤是急性呼吸窘迫综合征急性期的组织学标志,偶尔可以作为弥漫性肺泡出血。案例报告:我们向弥漫性肺泡出血和急性呼吸窘迫综合征的患者报告需要静脉静脉体外寿命的210天,他们在连续130天内成功治疗,没有静脉内抗凝。讨论:虽然有一些简短的报告详细说明了长期体外的救生人员支持,但文献主要缺乏关于长期体外寿命支持的数据,而无需完全全身抗凝。对体外膜氧合回路的定期检查是关键的,因为外部可见的血栓可以预测内部血栓产生,其具有全身栓塞或突然氧气衰竭的可能性。在我们的情况下,需要多个电路和氧气器的变化。结论:我们已经证明,患有对系统性抗凝凝血的禁忌症的患者可以安全地具有静脉静脉体外寿命支持,而不需要灾难性的血栓形成并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号